Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03991936 · ClinicalTrials.gov registry record · Phase 4
Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT03991936 is a Phase 4 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 11 participants.
The verdict
NCT03991936, a Phase 4 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.
Interventions
- DRUG Placebos
- DRUG Triamcinolone Acetonide 2.5 mg/mL
- DRUG Triamcinolone Acetonide 5.0 mg/mL
- DRUG Triamcinolone Acetonide 7.5 mg/mL
- DRUG Triamcinolone Acetonide 10 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-03-11 |
| Est. Completion | 2023-03-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03991936
The ClinicalTrials.gov registry entry for NCT03991936 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebos is the first listed.
NCT03991936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03991936 about?
NCT03991936 is a clinical study titled "Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis". This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.
What is the current status of trial NCT03991936?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2020-03-11. Estimated completion is 2023-03-29.
What interventions are being tested in trial NCT03991936?
The interventions under investigation include: Placebos (DRUG), Triamcinolone Acetonide 2.5 mg/mL (DRUG), Triamcinolone Acetonide 5.0 mg/mL (DRUG), Triamcinolone Acetonide 7.5 mg/mL (DRUG), Triamcinolone Acetonide 10 mg/mL (DRUG).
Who is sponsoring clinical trial NCT03991936?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.